Trial Profile

A Phase 1/2 Study of the Oral EGFR/HER2 Inhibitor TAK-788 in Japanese Non-Small Cell Lung Cancer Patients

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mobocertinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms J-EXCLAIM
Sponsors Takeda

Most Recent Events

15 May 2025 Planned End Date changed from 31 Mar 2025 to 30 Sep 2026.
12 Mar 2024 Planned End Date changed from 31 Mar 2024 to 31 Mar 2025.
01 Dec 2021 Planned primary completion date changed from 15 Sep 2021 to 31 Mar 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com